Poor
Not Aligned
Patient Risk:
High
Summary
Only precaution-related statements (anaphylaxis/hypersensitivity, CDAD, resistance, mononucleosis rash) were evaluated, but the provided assessment explicitly cannot confirm FDA-approved labeling and does not address major label domains (indications, dosing/administration, boxed warnings, contraindications, interactions, adverse reactions, monitoring, storage).
Category Scores
Accurate Statements
Amoxicillin should be discontinued and appropriate therapy instituted if an allergic reaction occurs.
Supported by the supplied excerpt labeled SECTION 5.1 (Anaphylactic Reactions), but FDA-approved label verification is not possible from the provided prompt.
Clostridium difficile-associated diarrhea (CDAD) has been reported with use of antibacterial agents including amoxicillin, and CDAD must be considered in patients with diarrhea after antibacterial use; ongoing antibiotic use not directed against C. difficile may need to be discontinued if suspected/confirmed.
Supported by the supplied excerpt labeled SECTION 5.2 (Clostridium difficile Associated Diarrhea), but FDA-approved label verification is not possible from the provided prompt.
Prescribing amoxicillin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit and increases the risk of drug-resistant bacteria.
Supported by the supplied excerpt labeled SECTION 5.3 (Development of Drug-Resistant Bacteria), but FDA-approved label verification is not possible from the provided prompt.
Amoxicillin should not be administered to patients with mononucleosis because a high percentage develop an erythematous skin rash.
Supported by the supplied excerpt labeled SECTION 5.4 (Use in Patients With Mononucleosis), but FDA-approved label verification is not possible from the provided prompt.
Unsupported Statements
The text you provided appears to be from an amoxicillin manufacturer package insert and contains label-relevant precaution language.
Not supported/verified against the FDA-approved prescribing information; the prompt explicitly states the latest FDA-approved label text could not be retrieved.
Supported: yes / Contradicted: no / Mentioned: yes (as an FDA label alignment conclusion).
This conclusion is not supported by the FDA-approved label because the prompt does not provide the actual FDA-approved label for a specific product/NDC and states verification is not possible.
Overall conclusion: Supported for the precaution-related statements included in Sections 5.1–5.4 as provided.
Whether the statements match the FDA-approved label cannot be confirmed; the assessment relies on non-FDA-provided excerpt context.
Contradictions
Important Omissions
Approved indication(s) and scope of use (specific labeled indications for amoxicillin/clavulanate products vs amoxicillin alone), including any population limitations stated in labeling.
Importance:
High
Dosage and administration instructions (dose, schedule, route, duration guidance, adjustments such as renal impairment, and how/when to take).
Importance:
High
Boxed warning(s) (if present in the FDA-approved label for the product).
Importance:
High
Contraindications section (beyond the mononucleosis precaution) including hypersensitivity and any other labeled contraindications.
Importance:
High
Drug interactions (e.g., any specific interactions described in the FDA-approved label).
Importance:
High
Adverse reactions (labeled adverse reactions list) and any warnings/precautions not covered by sections 5.1–5.4 in the provided excerpt.
Importance:
Moderate
Monitoring recommendations explicitly present in the FDA-approved label.
Importance:
Moderate
Storage and handling (if the FDA label includes specific instructions).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The provided evaluation cannot confirm FDA-approved label alignment and omits major safety-critical label domains (indications, dosing/administration, boxed warnings, contraindications, drug interactions, adverse reactions).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
FDA-approved label alignment cannot be verified because the assessment is based on non-provided/non-verifiable label text and does not evaluate key FDA label sections (indications, dosing, contraindications, boxed warnings, interactions, adverse reactions).
Suggested Improvement
Provide the exact FDA-approved label text (or DailyMed link) for a specific product/NDC, then re-evaluate alignment across the required label domains (indication, dosage/administration, boxed warnings, contraindications, warnings/precautions, drug interactions, adverse reactions, monitoring, and storage/handling).